---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-018275"
form_type: "8-K"
ticker: "GPCR"
cik: "0001888886"
company_name: "Structure Therapeutics Inc."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T02:37:29.204605+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Structure Therapeutics: aleniglipron studies fully enrolled; Q4 net loss $36.5M, cash $883.5M

## Summary
- ACCESS and ACCESS II studies fully enrolled on schedule; topline 36-week data expected by year-end 2025.
- Cash, cash equivalents and short-term investments $883.5M as of Dec 31, 2024; expected to fund operations through 2027.
- Net loss Q4 2024 $36.5M ($24.5M Q4 2023); FY2024 net loss $122.5M ($89.6M FY2023).
- Oral amylin agonist ACCG-2671: IND-enabling activities underway; Phase 1 initiation expected by year-end 2025.
- R&D expenses increased to $33.5M for Q4 2024 from $20.0M; full year $108.8M from $70.1M.

## SEC filing metadata
- accession: 0001104659-25-018275
- form_type: 8-K
- ticker: GPCR
- cik: 0001888886
- company_name: Structure Therapeutics Inc.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1888886/000110465925018275/0001104659-25-018275-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1888886/000110465925018275/tm257591d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-018275
- JSON: https://secwatch.observer/filing/0001104659-25-018275.json
- Plain text: https://secwatch.observer/filing/0001104659-25-018275.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.